Please login to the form below

Not currently logged in
Email:
Password:

Merck suspends Stimuvax programme

Merck has temporarily suspended its Stimuvax clinical programme after a patient developed encephalitis, an acute inflammation of the brain

Merck has temporarily suspended its Stimuvax (BLP25 liposome vaccine) clinical programme on a worldwide scale after a patient developed encephalitis, an acute inflammation of the brain.

The German pharmaceutical company has said that "effective immediately" all enrollments into trials and treatment of patients in current trials will be put on hold.

The decision was taken "in alignment with the US Food and Drug Administration's (FDA) clinical hold placed on the Investigational New Drug (IND) application for Stimuvax," according to Merck in a statement.

The Stimuvax vaccine is currently being tested in both phase II and phase III clinical trials for the treatment of non-small cell lung carcinoma (NSCLC) and breast cancer after being granted fast-track status in September 2004 by the FDA.

The patient who developed encephalitis was participating in a phase II exploratory trial using the vaccine in patients with multiple myeloma. This trial involved an intensified schedule of low-dose cyclophosphamide, a treatment not used in other Stimuvax studies.

The affected ongoing trials affected by the suspension include the NSCLC studies START and INSPIRE and the breast cancer study STRIDE.

"The company considers patient safety of paramount importance," said Merck "and will continue to work closely with the regulatory authorities, particularly with the FDA, to evaluate the implications of the adverse reaction on the clinical development programme for Stimuvax and determine the most suitable course of action."

23rd March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics